leisure time -WSS

leisure time

author：Wikipedia 2025-09-30 08:53:06 - browse：6652

A new asthma treatment that could be administered just once every six months has succeeded in two Phase 3 trials, developer GlaxoSmithKline announced Tuesday.

The drug, depemokimab, is designed to treat asthma by targeting a protein called interleukin-5, or IL-5. The protein is linked to the type of inflammation found in most severe asthma cases, according to the pharma company.

Depemokimab hit its primary endpoints in the trials, reducing asthma attacks over a year’s time frame. The company didn’t disclose exact details from the SWIFT-1 and SWIFT-2 trials.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Roche acquires Telavant from Roivant, adding experimental IBD treatment

focus

WSS

Results on Novartis prostate cancer therapy could expand its use

Private equity could exacerbate cardiology's overuse problem, experts fear

Long Covid needs a new name — and a new frame

Smaller biotechs seek to piggyback on weight loss drug boom

Acelyrin, a rare IPO success, stumbles in its first big test

J&J lung cancer data amount to new salvo against AstraZeneca

hotspot

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

Psychedelics group wrestles with new pharma identity

ADCs take center stage as promising cancer treatments

Novavax promises a turnaround & Lilly roils the obesity market

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

In age of alternative facts, a scholarly course on calling out crap

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

State Dept. review finds Biden bears some blame for Afghanistan failures

Long Covid needs a new name — and a new frame

After affirmative action ruling, medical educators look to 'holistic review'

Diverse clinical trials: Why aren’t we there yet?

focus

STAT Summit: Meghan O’Rourke on making chronic illness visible

Study on Amgen’s bispecific immunotherapy produces positive data

How to make the FDA’s new prescription one

How AI can help patients find reliable information about doctors

FDA proposes changes to key medical devices approval pathway

How AI can help patients find reliable information about doctors

hotspot

hotspot

focus

leisure time